Assessment of clinical and pharmacologic profile of tyrosine kinase inhibitors in the management of solid cancers and chronic myeloid leukemia

Abstract

newline Tyrosine kinase inhibitors (TKIs) have revolutionized cancer therapy by targeting specific molecular pathways involved in tumor growth and proliferation [1]. These agents are particularly effective in both solid tumors (e.g., hepatocellular carcinoma, renal cell carcinoma, non-small cell lung cancer) and hematologic malignancies (e.g., chronic myeloid leukemia, CML). However, the use of these agents in palliative care settings comes with unique challenges, particularly in patients whose clinical condition necessitates balancing treatment efficacy with quality of life. Research studies in India focusing specifically on the clinical profile of tyrosine kinase inhibitors (TKIs) in palliative care patients are limited. However, some studies have explored related aspects: While these studies contribute to understanding the broader context of palliative care and TKI use in India, comprehensive research specifically estimating the clinical profile of TKIs in palliative patients remains scarce. Understanding the clinical and pharmacologic nuances of TKIs in palliative care can guide clinicians in optimizing treatment strategies, improving patient outcomes, and advancing the field of oncology. By focusing on both solid and hematologic malignancies, this research seeks to bridge gaps in knowledge and provide a holistic view of the role of TKIs in modern cancer palliative care.